Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the Prolactin Suppression Induced by a Series of Full and Partial Dopamine D2 Receptor Agonists in Male Rats

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1992 Aug 1

PMID 1360151

Authors

A Ekman

E Eriksson

Affiliations

Soon will be listed here.

Abstract

The effect of pretreatment with a high dose of the alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) (20 mg/kg, 24 h) on the intrinsic activity displayed by a series of full and partial dopamine D2 receptor agonists on prolactin regulating pituitary D2 receptors in male rats was studied. To increase baseline prolactin levels, gamma-butyrolactone in a dose inhibiting brain dopamine neurotransmission was given to all animals. In controls, i.e. rats not given EEDQ, supramaximal doses of all full and partial D2 receptor agonists tested decreased serum prolactin levels with greater than 80%. While the intrinsic activities of the dopamine precursor 1-DOPA and of the full agonists (+)-3-PPP, 5-OH-DPAT, B-HT 920 (talipexole), apomorphine, and NPA (R-(-)-N-n-propylnorapomorphine) were not affected by pretreatment with EEDQ, the effects of supramaximal doses of the partial agonists (-)-HW-165, TDHL (terguride), SDZ208-911, (-)-3-PP) (preclamol), and SDZ 208-912 were reduced to 66%, 74%, 59%, 100%, and 100%, respectively. The effect of EEDQ on the intrinsic activity displayed by the various agonists corresponds inversely to the intrinsic efficacy displayed by the drugs in other models of D2 receptor function with one exception only; thus, the prolactin suppressive effect of (-)-3-PPP was more effectively antagonized by EEDQ than would have been predicted from the intrinsic efficacy usually attributed to the drug. Since the dose of EEDQ used in the present study has previously been shown not to decrease D2 receptor density in the pituitary as measured using in vivo radioligand binding, it is suggested that alkylation of D2 receptors may change the conformation of the individual receptor complexes in a way that decreases the responsiveness to partial but not full agonists.

References

Hamblin M, Creese I . Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sci. 1983; 32(19):2247-55. DOI: 10.1016/0024-3205(83)90423-x. View

Eriksson E, Svensson K, Clark D . The putative dopamine autoreceptor agonist B-HT 920 decreases nigral dopamine cell firing rate and prolactin release in rat. Life Sci. 1985; 36(19):1819-27. DOI: 10.1016/0024-3205(85)90154-7. View

Clark D, Hjorth S, Carlsson A . Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm. 1985; 62(3-4):171-207. DOI: 10.1007/BF01252236. View

Svensson K, Ekman A, Piercey M, Hoffmann W, Lum J, Carlsson A . Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn Schmiedebergs Arch Pharmacol. 1991; 344(3):263-74. DOI: 10.1007/BF00182999. View

Meller E, Bohmaker K, Namba Y, Friedhoff A, Goldstein M . Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol. 1987; 31(6):592-8. View

Meller E, Enz A, Goldstein M . Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity. Eur J Pharmacol. 1988; 155(1-2):151-4. DOI: 10.1016/0014-2999(88)90413-x. View

Cox R, Waszczak B . Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Mol Pharmacol. 1989; 35(1):125-31. View

Carlson J, Bergstrom D, Walters J . Stimulation of both D1 and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study. Brain Res. 1987; 400(2):205-18. DOI: 10.1016/0006-8993(87)90619-6. View

Hjorth S, Svensson K, Carlsson A, Wikstrom H, Andersson B . Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP. Naunyn Schmiedebergs Arch Pharmacol. 1986; 333(3):205-18. DOI: 10.1007/BF00512931. View

10.

Clark D, Hjorth S, Carlsson A . Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm. 1985; 62(1-2):1-52. DOI: 10.1007/BF01260414. View

11.

Meltzer H, Fang V . Effect of gamma-butyrolactone and baclofen on plasma prolactin in male rats. Biochem Pharmacol. 1977; 26(7):645-6. DOI: 10.1016/0006-2952(77)90040-5. View

12.

Cameron D, Crocker A . Alkylation of striatal dopamine receptors abolishes stereotyped behavior but has no effect on dopamine stimulated adenylate cyclase activity. Neurosci Lett. 1988; 90(1-2):165-71. DOI: 10.1016/0304-3940(88)90805-1. View

13.

Wachtel H, Dorow R . Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci. 1983; 32(4):421-32. DOI: 10.1016/0024-3205(83)90089-9. View

14.

Ekman A, Eriksson E . Pituitary and brain D2 receptor density measured in vitro and in vivo in EEDQ treated male rats. Life Sci. 1991; 48(4):321-31. DOI: 10.1016/0024-3205(91)90552-m. View

15.

Filipova M, Filip V, Macek Z, Mullerova S, Markova J, Kas S . Terguride in parkinsonism. A multicenter trial. Eur Arch Psychiatry Neurol Sci. 1988; 237(5):298-303. DOI: 10.1007/BF00450549. View

16.

Arnt J, Hyttel J . Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. J Neural Transm. 1984; 60(3-4):205-23. DOI: 10.1007/BF01249094. View

17.

Meller E, Puza T, Miller J, Friedhoff A, Schweitzer J . Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro. J Pharmacol Exp Ther. 1991; 257(2):668-75. View

18.

Coward D, Dixon K, Enz A, Shearman G, Urwyler S, White T . Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia. Psychopharmacol Bull. 1989; 25(3):393-7. View

19.

Ekman A, Quiding M, Eriksson E . Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats. Life Sci. 1991; 48(4):311-20. DOI: 10.1016/0024-3205(91)90551-l. View

20.

Carlsson M, Carlsson A, Eriksson E . The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats. Eur J Pharmacol. 1987; 142(1):39-43. DOI: 10.1016/0014-2999(87)90651-0. View